Anticoagulation and antiplatelet therapy in implantation of electrophysiological devices

Europace

Volumn 13, Issue 12, 2011, Pages 1669-1680

  Korantzopoulos, Panagiotis ^a   Letsas, Konstantinos P ^b   Liu, Tong ^c   Fragakis, Nikolaos ^d   Efremidis, Michael ^b   Goudevenos, John A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Anticoagulation; Antiplatelets; Antithrombotic therapy; Bleeding; Device implantation; Implantable cardioverterdefibrillators; Pacemakers; Pocket haematoma

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; HEPARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTIFICIAL HEART PACEMAKER; BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR RISK; ELECTROPHYSIOLOGY; FOLLOW UP; HEMATOMA; HOSPITALIZATION; HUMAN; IMPLANTATION; INCIDENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR;

ANTICOAGULANTS; ARRHYTHMIAS, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEMATOMA; HEMORRHAGE; HUMANS; PACEMAKER, ARTIFICIAL; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 81855194797     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur210     Document Type: Review

References (57)

1. Sutton R, Fisher JD, Linde C, Benditt DG. History of electrical therapy for the heart. Eur Heart J Suppl 2007;9(Suppl. I):I3-I10.
2. Ellenbogen KA, Kay GN, Lau CP, Wilkoff BL (Eds). Clinical Cardiac Pacing, Defibrilla-tion, and Resynchronization Therapy. 3rd edn. Philadelphia: Saunders Elsevier; 2007.
3. Kusumoto FM, Goldschlager NF (Eds). Cardiac Pacing for the Clinician. 2nd ed. New York: Springer Science; 2008.
4. Uslan DZ, Tleyjeh IM, Baddour LM, Friedman PA, Jenkins SM, St Sauver JL et al. Temporal trends in permanent pacemaker implantation: a population-based study. Am Heart J 2008;155:896-903.
5. Ector H, Vardas P, On the behalf of the European Heart Rhythm Association, European Society of Cardiology. Current use of pacemakers, implantable cardio-verter defibrillators, and resynchronization devices: data from the European Heart Rhythm Association. Eur Heart J Suppl 2007;9(Suppl. I):I44-I9.
6. Wiegand UK, LeJeune D, Boguschewski F, Bonnemeier H, Eberhardt F, Schunkert H et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and peri-operative antiplatelet/anticoagulation therapy. Chest 2004;126:1177-86. (Pubitemid 39391248)
7. Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N et al. PEOPLE Study Group. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation 2007; 116:1349-55. (Pubitemid 47417560)
8. Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE et al. Dual anti-platelet therapy and heparin 'bridgingapos significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter- defibrillator device implantation. J Am Coll Cardiol 2010;55:2376-82.
9. Lekkerkerker JC, van Nieuwkoop C, Trines SA, van der Bom JG, Bernards A, van de Velde ET et al. Risk factors and time delay associated with cardiac device infections: Leiden device registry. Heart 2009;95:715-20.
10. Poole JE, Gleva MJ, Mela T, Chung MK, Uslan DZ, Borge R et al. REPLACE Registry Investigators. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 2010;122:1553-61.
11. Mahapatra S, Bybee KA, Bunch TJ, Espinosa RE, Sinak LJ, McGoon MD et al. Incidence and predictors of cardiac perforation after permanent pacemaker placement. Heart Rhythm 2005;2:907-11. (Pubitemid 41372273)
12. Carlson MD, Freedman RA, Levine PA. Lead perforation: incidence in registries. Pacing Clin Electrophysiol 2008;31:13-5.
13. Hirschl DA, Jain VR, Spindola-Franco H, Gross JN, Haramati LB. Prevalence and characterization of asymptomatic pacemaker and ICD lead perforation on CT. Pacing Clin Electrophysiol 2007;30:28-32. (Pubitemid 46114925)
14. Gras D, Böcker D, Lunati M, Wellens HJ, Calvert M, Freemantle N et al. CARE-HF Study Steering Committee and Investigators. Implantation of cardiac resynchroni-zation therapy systems in the CARE-HF trial: procedural success rate and safety. Europace 2007;9:516-22. (Pubitemid 47249440)
15. Krahn AD, Healey JS, Simpson CS, Essebag V, Sivakumaran S, Birnie DH. Anticoagu-lation of patients on chronic warfarin undergoing arrhythmia device surgery: wide variability of perioperative bridging in Canada. Heart Rhythm 2009;6:1276-9.
16. de Bono J, Nazir S, Ruparelia N, Bashir Y, Betts T, Rajappan K. Perioperative management of anticoagulation during device implantation-the UK perspective. Pacing Clin Electrophysiol 2010;33:389-93.
17. Goldstein DJ, Losquadro W, Spotnitz HM. Outpatient pacemaker procedures in orally anticoagulated patients. Pacing Clin Electrophysiol 1998;21:1730-4. (Pubitemid 28415469)
18. Marquie C, De Geeter G, Klug D, Kouakam C, Brigadeau F, Jabourek O et al. Post-operative use of heparin increases morbidity of pacemaker implantation. Europace 2006;8:283-7. (Pubitemid 43905736)
19. Przybylski A, Derejko P, Kwasniewski W, Urbańczyk-Swić D, Zakrzewska J, Orszulak W et al. Bleeding complications after pacemaker or cardioverter-defibrillator implantation in patients receiving dual antiplatelet therapy: results of a prospective, two-centre registry. Neth Heart J 2010;18:230-5.
20. Kutinsky IB, Jarandilla R, Jewett M, Haines DE. Risk of hematoma complications after device implant in the clopidogrel era. Circ Arrhythm Electrophysiol 2010;3: 312-8.
21. Chauhan A, Grace AA, Newell SA, Stone DL, Shapiro LM, Schofield PM et al. Early complications after dual chamber versus single chamber pacemaker implantation. Pacing Clin Electrophysiol 1994;17:2012-5. (Pubitemid 24362940)
22. Tolosana JM, Berne P, Mont L, Heras M, Berruezo A, Monteagudo J et al. Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. Eur Heart J 2009;30:1880-4.
23. Pakarinen S, Oikarinen L, Toivonen L. Short-term implantation-related complications of cardiac rhythm management device therapy: a retrospective single-centre 1-year survey. Europace 2010;12:103-8.
24. Ghanbari H, Feldman D, Schmidt M, Ottino J, Machado C, Akoum N et al. Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol 2010;33:400-6.
25. Ahmed I, Gertner E, Nelson WB, House CM, Zhu DW. Chronic kidney disease is an independent predictor of pocket hematoma after pacemaker and defibrillator implantation. J Interv Card Electrophysiol 2010;29:203-7.
26. Aggarwal RK, Connelly DT, Ray SG, Ball J, Charles RG. Early complications of permanent pacemaker implantation: no difference between dual and single chamber systems. Br Heart J 1995;73:571-5.
27. Grubb BP, Welch M, Kanjwal K, Karabin B, Kanjwal Y. An anatomic-based approach for the placement of implantable loop recorders. Pacing Clin Electrophy-siol 2010;33:1149-52.
28. Tischenko A, Gula LJ, Yee R, Klein GJ, Skanes AC, Krahn AD. Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin. Am Heart J 2009;158:252-6.
29. Chow V, Ranasinghe I, Lau J, Stowe H, Bannon P, Hendel N et al. Peri-procedural anticoagulation and the incidence of haematoma formation after permanent pacemaker implantation in the elderly. Heart Lung Circ 2010;19:706-12.
30. Dreger H, Grohmann A, Bondke H, Gast B, Baumann G, Melzer C. Is antiarrhyth-mia device implantation safe under dual antiplatelet therapy? Pacing Clin Electrophy-siol 2010;33:394-9.
31. Nowak B, Misselwitz B, Erdogan A, Funck R, Irnich W, Israel CW et al. Expert committee 'Pacemakerapos, Institute of Quality Assurance. Do gender differences exist in pacemaker implantation?-results of an obligatory external quality control program. Europace 2010;12:210-5.
32. Robinson M, Healey JS, Eikelboom J, Schulman S, Morillo CA, Nair GM et al. Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrilla-tors. Pacing Clin Electrophysiol 2009;32:378-82.
33. Peterson PN, Daugherty SL, Wang Y, Vidaillet HJ, Heidenreich PA, Curtis JP et al., National Cardiovascular Data Registry. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. Circulation 2009;119:1078-84.
34. van Eck JW, van Hemel NM, Zuithof P, van Asseldonk JP, Voskuil TL, Grobbee DE et al. Incidence and predictors of in-hospital events after first implantation of pacemakers. Europace 2007;9:884-9. (Pubitemid 351773301)
35. Cano O, Osca J, Sancho-Tello MJ, Olagüe J, Castro JE, Salvador A. Morbidity associated with three different antiplatelet regimens in patients undergoing implantation of cardiac rhythm management devices. Europace 2011;13:395-401.
36. Riddell JW, Chiche L, Plaud B, Hamon M. Coronary stents and noncardiac surgery. Circulation 2007;116:e378-e82.
37. Thachil J, Gatt A, Martlew V. Management of surgical patients receiving anticoa-gulation and antiplatelet agents. Br J Surg 2008;95:1437-48.
38. Möllmann H, Nef HM, Hamm CW, Elsässer A. How to manage patients with need for antiplatelet therapy in the setting of (un-)planned surgery. Clin Res Cardiol 2009;98:8-15.
39. Llau JV, Lopez-Forte C, Sapena L, Ferrandis R. Perioperative management of anti-platelet agents in noncardiac surgery. Eur J Anaesthesiol 2009;26:181-7.
40. Phan TG, Koh M, Wijdicks EF. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol 2000;57:1710-3.
41. Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008;168:63-9.
42. Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009; 119:1634-42.
43. Abualsaud AO, Eisenberg MJ. Perioperative management of patients with drug-eluting stents. JACC Cardiovasc Interv 2010;3:131-42.
44. Michaud GF, Pelosi F Jr, Noble MD, Knight BP, Morady F, Strickberger SA. A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibril-lator implantation. J Am Coll Cardiol 2000;35:1915-8. (Pubitemid 30342875)
45. Thal S, Moukabary T, Boyella R, Shanmugasundaram M, Pierce MK, Thai H et al. The relationship between warfarin, aspirin, and clopidogrel continuation in the peri-procedural period and the incidence of hematoma formation after device implantation. Pacing Clin Electrophysiol 2010;33:385-8.
46. Al-Khadra AS. Implantation of pacemakers and implantable cardioverter defibrillators in orally anticoagulated patients. Pacing Clin Electrophysiol 2003;26: 511-4. (Pubitemid 36399207)
47. Giudici MC, Barold SS, Paul DL, Bontu P. Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy. Pacing Clin Electro-physiol 2004;27:358-60. (Pubitemid 38352516)
48. Milic DJ, Perisic ZD, Zivic SS, Stanojkovic ZA, Stojkovic AM, Karanovic ND et al. Prevention of pocket related complications with fibrin sealant in patients undergoing pacemaker implantation who are receiving anticoagulant treatment. Euro-pace 2005;7:374-9. (Pubitemid 40790423)
49. Cheng M, Hua W, Chen K, Pu J, Ren X, Zhao X et al. Perioperative anticoagula-tion for patients with mechanic heart valve(s) undertaking pacemaker implantation. Europace 2009;11:1183-7.
50. Ahmed I, Gertner E, Nelson WB, House CM, Dahiya R, Anderson CP et al. Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation. Heart Rhythm 2010;7:745-9.
51. Cheng A, Nazarian S, Brinker JA, Tompkins C, Spragg DD, Leng CT et al. Continuation of warfarin during pacemaker or implantable cardioverter- defibrillator implantation: A randomized clinical trial. Heart Rhythm 2011;8: 536-40.
52. Jamula E, Douketis JD, Schulman S. Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide. J Thromb Haemost 2008;6:1615-21.
53. Daubert JC, Mabo P. Continue or withhold oral anticoagulation in high-risk patients undergoing pacemaker or ICD implantation. Eur Heart J 2009; advance access publication 28 August 2009, doi:10.1093/eurheartj/EHN491.
54. Love CJ. Perioperative management of anticoagulation in patients undergoing cardiac rhythm device procedures: a bridge to nowhere? Pacing Clin Electrophysiol 2010;33:383-4.
55. Tompkins C, Henrikson CA. Optimal strategies for the management of antiplate-let and anticoagulation medications prior to cardiac device implantation. Cardiol J 2011;18:103-9.
56. TM versus standard of care. Int J Cardiol 2011; online publish ahead of print 3 March 2011, doi:10.1016/j.ijcard.2011.02. 042.
57. Birnie D, Healey JS, Krahn A, Essebag V, Sivakumaran S, Tang A et al. Bridge or continue Coumadin for device surgery: a randomized controlled trial rationale and design. Curr Opin Cardiol 2009;24:82-7.